For Adult Patients With Moderately to Severely Active CD

*In both the CD and UC studies, many patients achieved clinical remission at 1 year with STELARA®.

Rapid Response1

Many patients achieved clinical response at Week 6 and 70-point response as early as Week 3 in clinical studies

Lasting Remission2

Many patients achieved clinical remission at 1 year in a clinical study

Safety Profile1

The overall safety profile of STELARA® at 1 year in CD was consistent with that seen in other approved indications

Resources to help your patients

Local Coverage

Commercial Formulary Coverage Look-up

Enter Your ZIP Code to View Coverage Results

Please enter zip code  

All information is subject to change. Actual benefits determined by health plan. We strongly recommend you call the health plan for its reimbursement policies. This information does not advise on or guarantee coverage or payment.


Janssen CarePath can help make it simple for you to help your patients

Janssen CarePath is your one source for access, affordability, and treatment support for your patients. Our dedicated Care Coordinator team supports the Janssen medications you prescribe. We can help make it easier for you and your patients to get the resources you both may need. Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on STELARA®.

Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support available.

Sign Up or Log In to the Provider Portal at where you can request and review benefits investigations, enroll eligible patients in the Janssen CarePath Savings Program and view Savings Program transactions as requested by the patient.


CD=Crohn's disease; UC=ulcerative colitis.


References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.